ABLYNX ANNOUNCES WARRANT EXERCISE
(Thomson Reuters ONE) - GHENT, Belgium, 30 October 2009 - Ablynx [Euronext Brussels: ABLX]today announced that an additional 4,407 common shares have beenissued by the Company in exchange for ?6,732.60 as the result of theexercise of warrants by some employees and consultants of theCompany.As a result of this transaction, Ablynx now has 36,889,789 sharesoutstanding. -ends-About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.comFounded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceuticalcompany focused on the discovery and development of Nanobodies®, anovel class of therapeutic proteins based on single-domain antibodyfragments, for a range of serious and life-threatening humandiseases. The Company currently has over 220 employees. Ablynxcompleted a successful IPO on Euronext Brussels [ABLX] on 7 November2007.Ablynx is developing a portfolio of Nanobody®-based therapeutics in anumber of major disease areas, including inflammation, thrombosis,oncology and Alzheimer's disease. Nanobodies® have been generatedagainst more than 150 different disease targets. Efficacy data havebeen obtained in over 26 in vivo models for Nanobodies® against arange of different targets.Ablynx has an extensive patent position in the field of Nanobodies®for healthcare applications. It has exclusive and worldwide rights tomore than 50 families of granted patents and pending patentapplications, including the Hamers patents covering the basicstructure, composition, preparation and uses of Nanobodies®.Ablynx has ongoing research collaborations and significantpartnerships with several major pharmaceutical companies, includingBoehringer Ingelheim, Merck Serono, Novartis and WyethPharmaceuticals. Ablynx is building a diverse and broad portfolio oftherapeutic Nanobodies® through these collaborations as well asthrough its own internal discovery programmes.For more information, please contact:College Hill Life Sciences - for International media enquiries:Sue Charles, Justine Lamond, Dr John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr. Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comWim OttevaereChief Financial Officert: +32 (0)9 262 00 11e: wim.ottevaere(at)ablynx.comhttp://hugin.info/137912/R/1351557/326688.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 30.10.2009 - 18:00 Uhr
Sprache: Deutsch
News-ID 7701
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 311 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES WARRANT EXERCISE"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
